Antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Other Product-Specific Information:
Levetiracetam: the profile of a novel anticonvulsant drug - part I: preclinical data.
Smedt et al.
CNS Drug Rev., 2007;13:43
Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection.
Ueda et al.
Brain Res., 2007;1151:55
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Lynch et al.
Proct.Natl.Acad.Sci. USA, 2004;101:9861